The database will offer drug developers the ability to track and monitor markets, competition, and technological and scientific efforts, the company said. The database covers the following metrics:

• Virus type and family
• Genome types
• Genes deleted and transgenes
• Pathway or signaling alternation
• Envelope modifications or promoter-related modifications
• Routes of administration
• Diseases
• Biomarkers
• Line of therapy

The data consists of information taken from a range of sources, including clinical trial registries, scientific journals, company reports, press releases, conference reports and abstracts, and government or regulatory organizations, Beacon said.

Scientists urge that surveillance of a new SARS-CoV-2 variant is necessary
A SARS-CoV-2 variant carrying an amino acid change, D614G, in the spike protein has become the predominant form of the virus in the current global pandemic....

Computer tools shorten development time for SARS-CoV-2 drugs
Computer-based tools are helping researchers find potentially promising candidates for vaccines and treatments for SARS-CoV-2 -- and much more quickly...

Imagia, Illumina partner to advance precision medicine
Healthcare artificial intelligence firm Imagia is partnering with Illumina on a project to further advance the development of precision medicine using...

New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published...

Directed evolution shows promise in reducing drug discovery times
A research collaboration between scientists at the University of Leeds and AstraZeneca resulted in the development of a technique that can significantly...